{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:29:20Z","timestamp":1782019760940,"version":"3.54.5"},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2016,8]]},"abstract":"Summary<\/jats:title>\n \n The aim of this study is to analyse the risk of invasive fungal infection (\n IFI<\/jats:styled-content>\n ) and the need for antifungal prophylaxis in patients with acute myeloid leukaemia and myelodysplastic syndromes (\n AML<\/jats:styled-content>\n \/\n MDS<\/jats:styled-content>\n ) treated with azacitidine. We retrospectively analysed the incidence of\n IFI<\/jats:styled-content>\n according to\n EORTC<\/jats:styled-content>\n \u2010\n MSG<\/jats:styled-content>\n criteria in 121 consecutive\n AML<\/jats:styled-content>\n \/\n MDS<\/jats:styled-content>\n patients receiving 948 azacitidine courses (median 5, range 1\u201343) between June 2007 and June 2015. Four cases of\n IFI<\/jats:styled-content>\n (two possible, one probable aspergillosis and one proven candidemia) occurred in this series. The incidence rate of proven\/probable\n IFI<\/jats:styled-content>\n was 0.21% per treatment cycle and 1.6% per patient treated for the whole series, and 0.73% per treatment cycle and 4.1% per patient treated in those with severe neutropenia. Two patients died from\n IFI<\/jats:styled-content>\n , leading to an\n IFI<\/jats:styled-content>\n \u2010attributable mortality rate of 1.65% per patient and 0.21% per treatment cycle. The numbers needed to treat with prophylaxis to prevent one case of\n IFI<\/jats:styled-content>\n are 238 azacitidine cycles or 30 patients throughout their whole treatment course, and 137 azacitidine cycles or 24 patients among those with severe neutropenia.\n AML<\/jats:styled-content>\n \/\n MDS<\/jats:styled-content>\n patients treated with azacitidine, including those with severe prolonged neutropenia, have a very low risk of\n IFI<\/jats:styled-content>\n which does not justify the use of antifungal prophylaxis.\n <\/jats:p>","DOI":"10.1111\/myc.12500","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T20:09:30Z","timestamp":1459368570000},"page":"516-519","source":"Crossref","is-referenced-by-count":45,"title":["Invasive fungal infections in\n AML<\/scp>\n \/\n MDS<\/scp>\n patients treated with azacitidine: a risk worth considering antifungal prophylaxis?"],"prefix":"10.1111","volume":"59","author":[{"given":"Helena","family":"Pomares","sequence":"first","affiliation":[{"name":"Department of Haematology Catalan Institute of Oncology \u2013 Hospital Duran i Reynals Biomedical Research Institute of Bellvitge (Idibell) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[{"name":"Department of Haematology Catalan Institute of Oncology \u2013 Hospital Duran i Reynals Biomedical Research Institute of Bellvitge (Idibell) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"S\u00e1nchez\u2010Ortega","sequence":"additional","affiliation":[{"name":"Department of Haematology Catalan Institute of Oncology \u2013 Hospital Duran i Reynals Biomedical Research Institute of Bellvitge (Idibell) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Department of Haematology Catalan Institute of Oncology \u2013 Hospital Duran i Reynals Biomedical Research Institute of Bellvitge (Idibell) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Haematology Catalan Institute of Oncology \u2013 Hospital Duran i Reynals Biomedical Research Institute of Bellvitge (Idibell) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.175"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0146"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12426"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.0854"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.173"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.03.004"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.063420"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu673"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_6_13_1","unstructured":"DonnellyJP CordonnierC Cuenca\u2010EstrellaMet al.A European period\u2010prevalence study to estimate the rate of invasive pulmonary mould disease (PIMDA study). European Congress Clinical Microbiology and Infectious Diseases 2014 Barcelona Spain. Abstract P0028a."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-9-199705010-00007"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068266"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.09.014"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.030"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.001"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.4161\/viru.1.3.11750"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12500","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T20:02:58Z","timestamp":1696190578000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/myc.12500"],"URL":"https:\/\/doi.org\/10.1111\/myc.12500","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726254736.793523024","asserted-by":"object"}]},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}